For research teamsHelp me find a study
Back to all studies
CompletedNCT00102518

Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) for schizophrenia

This study is completed in the United States. It is testing Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) for schizophrenia.

Schizophrenia, BipolarityDrugFrom 10 Years to 17 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Aripiprazole may be useful for adolescents experiencing schizophrenia.

What would participation involve?

Participants may receive Aripiprazole, attend study visits with the research team. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adolescents with schizophrenia. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateSeptember 2004
Recruitment status
Completed
Enrollment listed in the registry
325
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 10 Years to 17 Years
Official registry ID
NCT00102518
Official title
A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00102518. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 50 sites
  • Local Institution
    Birmingham, Alabama
    Site status: Not listed — confirm with the team
  • Local Institution
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Local Institution
    Costa Mesa, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Fresno, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Orange, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Riverside, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Rosemead, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Sacramento, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Temecula, California
    Site status: Not listed — confirm with the team
  • Local Institution
    Washington D.C., District of Columbia
    Site status: Not listed — confirm with the team
  • Local Institution
    Altamonte Springs, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Fort Lauderdale, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Hialeah, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Jacksonville, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Orange City, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Tampa, Florida
    Site status: Not listed — confirm with the team
  • Local Institution
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Local Institution
    Honolulu, Hawaii
    Site status: Not listed — confirm with the team
  • Local Institution
    Chicago, Illinois
    Site status: Not listed — confirm with the team
  • Local Institution
    Kansas City, Kansas
    Site status: Not listed — confirm with the team
  • Local Institution
    Lexington, Kentucky
    Site status: Not listed — confirm with the team
  • Local Institution
    Louisville, Kentucky
    Site status: Not listed — confirm with the team
  • Local Institution
    Lake Charles, Louisiana
    Site status: Not listed — confirm with the team
  • Local Institution
    Metairie, Louisiana
    Site status: Not listed — confirm with the team
  • Local Institution
    New Orleans, Louisiana
    Site status: Not listed — confirm with the team
  • Local Institution
    Somerville, Massachusetts
    Site status: Not listed — confirm with the team
  • Local Institution
    Clinton, Michigan
    Site status: Not listed — confirm with the team
  • Local Institution
    Kansas City, Missouri
    Site status: Not listed — confirm with the team
  • Local Institution
    Saint Charles, Missouri
    Site status: Not listed — confirm with the team
  • Local Institution
    Elmsford, New York
    Site status: Not listed — confirm with the team
  • Local Institution
    New York, New York
    Site status: Not listed — confirm with the team
  • Local Institution
    Olean, New York
    Site status: Not listed — confirm with the team
  • Local Institution
    Rochester, New York
    Site status: Not listed — confirm with the team
  • Local Institution
    Chapel Hill, North Carolina
    Site status: Not listed — confirm with the team
  • Local Institution
    Cleveland, Ohio
    Site status: Not listed — confirm with the team
  • Local Institution
    Lyndhurst, Ohio
    Site status: Not listed — confirm with the team
  • Local Institution
    Oklahoma City, Oklahoma
    Site status: Not listed — confirm with the team
  • Local Institution
    Bala-Cynwyd, Pennsylvania
    Site status: Not listed — confirm with the team
  • Local Institution
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • Local Institution
    Memphis, Tennessee
    Site status: Not listed — confirm with the team
  • Local Institution
    Bellaire, Texas
    Site status: Not listed — confirm with the team
  • Local Institution
    DeSoto, Texas
    Site status: Not listed — confirm with the team
  • Local Institution
    Houston, Texas
    Site status: Not listed — confirm with the team
  • Local Institution
    San Antonio, Texas
    Site status: Not listed — confirm with the team
  • Local Institution
    Salt Lake City, Utah
    Site status: Not listed — confirm with the team
  • Local Institution
    Kirkland, Washington
    Site status: Not listed — confirm with the team
  • Local Institution
    Seattle, Washington
    Site status: Not listed — confirm with the team
  • Local Institution
    Spokane, Washington
    Site status: Not listed — confirm with the team
  • Local Institution
    Wauwatosa, Wisconsin
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Aripiprazole. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 10 Years to 17 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., which appears to be a pharmaceutical company. Sponsor website: https://www.otsuka.co.jp/en/. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.